WIB22: Suma Krishnan co-founded a company to develop a treatment for ‘the worst disease you’ve never heard of’
This profile is part of Endpoints News’ 2022 special report about Women in Biopharma R&D. You can read the full report here.
After spending time with patients who were diagnosed with what some call “the worst disease you’ve never heard of,” Suma Krishnan dedicated herself to finding a treatment.
Krishnan, who is the co-founder and chief operating officer of Krystal Biotech, spearheaded a gene therapy gel that showed promise in a late-stage clinical trial for dystrophic epidermolysis bullosa. The FDA is reviewing whether to approve the therapy and will decide by February.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.